MétaCan
Menu
← Back to cohort
Record W4414800233 · doi:10.1093/neuonc/noaf193.286

P08.18.B PROSPECTIVE EVALUATION OF NEUROLOGICAL SAFETY AFTER ANTI-BCMA CAR T-CELL THERAPY IN A SINGLE-CENTRE COHORT

2025· article· en· W4414800233 on OpenAlexaboutno aff
Claudia Bârsan, Rénata Ursu, Stéphanie Harel, Catherine Belin, Christophe Carreau, M El Soudany, Nicolae Crainic, Valter Duro Garcı́a, Bruno Royer, Stefania Cuzzubbo, Bertrand Arnulf, Alain Carpentier

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsnot available
Fundersnot available
KeywordsNeurocognitiveCohortProspective cohort studyNeurotoxicityCognitionPost-concussion syndromeNeurological examinationCohort study

Abstract

fetched live from OpenAlex

Abstract BACKGROUND Anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cell therapy has demonstrated high efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). Acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), typically occur within two weeks of infusion and resolve promptly. However, data on long-term neurological safety remain scarce. Emerging evidence suggests the possibility of movement and neurocognitive treatment-emergent toxicities (MNTs), characterised by irreversible parkinsonism, cognitive impairment, and personality changes, typically arising a median of 36 days [range: 14-914] after CRS/ICANS resolution. This study aims to prospectively assess the long-term neurological safety of ide-cel in R/R MM patients, using standardized cognitive and motor evaluations. MATERIAL AND METHODS We conducted a prospective, systematic neurological evaluation in a cohort of R/R MM patients treated with ide-cel between November 2021 and December 2024 at our center. Only progression-free patients were included. Neurological assessments were performed by a neurologist at baseline (≤2 months before infusion) and at follow-up visits up to 18 months [range 10.5-17.3} post-infusion. Assessments included the Montreal Cognitive Assessment (MoCA) for global cognitive function and the motor subscale of the Unified Parkinson’s Disease Rating Scale (UPDRS) for extrapyramidal symptoms. Pre-treatment brain MRI (<3 months) excluded structural abnormalities. CRS and ICANS were retrospectively recorded. Neurotoxicity triggered further neurological assessment. RESULTS Among 88 patients treated with ide-cel, 40 were excluded due to early relapse, death, or loss to follow-up. Of the 48 eligible patients, 27 remain in follow-up, and 21 have completed full neurological assessments. At baseline, the median MoCA score was 26/30. The highest UPDRS motor score was 4/56, observed in two patients. ICANS was reported in three patients (two Grade 1 and one Grade 4 requiring ICU care). Cognitive and motor scores remained stable between baseline and follow-up assessments, including in those with initially elevated UPDRS scores. CONCLUSION In this real-world, prospective cohort of ide-cel-treated R/R MM patients, no long-term cognitive or motor deterioration was observed up to 18 months post-infusion. Despite the limited number of patients evaluable at this time point, these preliminary findings support the long-term neurological safety of ide-cel when patients are systematically assessed using standardized tools such as the MoCA and UPDRS. Updated results will be presented at the EANO meeting.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.351
Teacher spread0.311 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicCAR-T cell therapy research→French-language works237,207→